First Manhattan
AMAM

First Manhattan’s Ambrx Biopharma Inc AMAM Stock Holding History

First Manhattan’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-135,003
Closed -$1.55M – 1602
2023
Q3 		$1.55M Hold
135,003
– – 0.01% 337
2023
Q2 		$2.22M Buy
+135,003
New +$1.7M 0.01% 291

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

First Manhattan's AMAM Position: Q4 2023 in Review

First Manhattan sold out of Ambrx Biopharma Inc (AMAM) in Q4 2023, closing a stake of 135,003 shares — an estimated $1.55M sold.

First Manhattan first reported a position in AMAM in Q2 2023 and held it in 2 quarters. The position peaked at $2.22M in Q2 2023. 68 funds tracked by Wall St. Rank hold AMAM as of Q4 2023.

  • First Manhattan reported no remaining Ambrx Biopharma Inc position as of Q4 2023 after selling out during the quarter.
  • First Manhattan sold 135,003 Ambrx Biopharma Inc shares in Q4 2023, an estimated $1.55M.
  • First Manhattan first reported a position in Ambrx Biopharma Inc in Q2 2023 and held it in 2 quarters.
  • First Manhattan's Ambrx Biopharma Inc position peaked at $2.22M in Q2 2023.
  • 68 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q4 2023.

Based on First Manhattan's 13F filing for Q4 2023, filed 13 Feb 2024.